Novel rare variants in congenital cardiac arrhythmia genes are frequent in drug-induced torsades de pointes

被引:0
|
作者
A H Ramirez
C M Shaffer
J T Delaney
D P Sexton
S E Levy
M J Rieder
D A Nickerson
A L George
D M Roden
机构
[1] Vanderbilt University,Department of Medicine
[2] Center for Human Genetics Research,Department of Biomedical Informatics
[3] Vanderbilt University,Department of Genome Sciences
[4] Vanderbilt University,Department of Pharmacology
[5] HudsonAlpha Institute for Biotechnology,undefined
[6] University of Washington,undefined
[7] Vanderbilt University,undefined
来源
关键词
adverse drug reaction; next-generation sequencing; sudden cardiac death;
D O I
暂无
中图分类号
学科分类号
摘要
Marked prolongation of the QT interval and polymorphic ventricular tachycardia following medication (drug-induced long QT syndrome, diLQTS) is a severe adverse drug reaction (ADR) that phenocopies congenital long QT syndrome (cLQTS) and is one of the leading causes for drug withdrawal and relabeling. We evaluated the frequency of rare non-synonymous variants in genes contributing to the maintenance of heart rhythm in cases of diLQTS using targeted capture coupled to next-generation sequencing. Eleven of 31 diLQTS subjects (36%) carried a novel missense mutation in genes with known congenital arrhythmia associations or with a known cLQTS mutation. In the 26 Caucasian subjects, 23% carried a highly conserved rare variant predicted to be deleterious to protein function in these genes compared with only 2–4% in public databases (P<0.003). We conclude that the rare variation in genes responsible for congenital arrhythmia syndromes is frequent in diLQTS. Our findings demonstrate that diLQTS is a pharmacogenomic syndrome predisposed by rare genetic variants.
引用
收藏
页码:325 / 329
页数:4
相关论文
共 50 条
  • [21] Which pathological condition is the most critical for drug-induced torsades de pointes?
    Chiba, Katsuyoshi
    Takasuna, Kiyoshi
    Sanbuissho, Atsushi
    Sugiyama, Atsushi
    JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 2012, 66 (02) : 194 - 194
  • [22] Drug-induced Torsades de Pointes in patients aged 80 years or more
    Paran, Yael
    Mashav, Noa
    Henis, Oren
    Swartzon, Michael
    Arbel, Yaron
    Justo, Dan
    ANATOLIAN JOURNAL OF CARDIOLOGY, 2008, 8 (04): : 260 - 265
  • [23] Drug-induced torsades de pointes - A form of mechano-electric feedback?
    Fabritz, Larissa
    CARDIOVASCULAR RESEARCH, 2007, 76 (02) : 202 - 203
  • [24] Drug-induced QT prolongation and torsades de pointes: evaluation of a QT nomogram
    Chan, A.
    Isbister, G. K.
    Kirkpatrick, C. M. J.
    Dufful, S. B.
    QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2007, 100 (10) : 609 - 615
  • [25] Predicting the degree of drug-induced QT prolongation and the risk for torsades de pointes
    Ding, Chunhua
    HEART RHYTHM, 2011, 8 (10) : 1535 - 1536
  • [26] The hERG potassium channel and hERG screening for drug-induced torsades de pointes
    Hancox, Jules C.
    McPate, Mark J.
    El Harchi, Aziza
    Zhang, Yi Hong
    PHARMACOLOGY & THERAPEUTICS, 2008, 119 (02) : 118 - 132
  • [27] Early clinical development: Evaluation of drug-induced torsades de pointes risk
    Vik, Torbjorn
    Pollard, Chris
    Sager, Philip
    PHARMACOLOGY & THERAPEUTICS, 2008, 119 (02) : 210 - 214
  • [28] DRUG-INDUCED TORSADES-DE-POINTES - A POSSIBLE INTERACTION OF TERFENADINE AND ERYTHROMYCIN
    BIGLIN, KE
    FARAON, MS
    CONSTANCE, TD
    LIEHLAI, M
    ANNALS OF PHARMACOTHERAPY, 1994, 28 (02) : 282 - 282
  • [29] Rote of transmural dispersion of repolarization in the genesis of drug-induced torsades de pointes
    Antzelevitch, C
    HEART RHYTHM, 2005, 2 : S9 - S15
  • [30] A novel monkey proarrhythmia model that can predict the drug-induced torsades de pointes in clinical practice
    Satoh, Y
    Sugiyama, A
    Takahara, A
    Sakamoto, K
    Sakamoto, M
    Nomura, M
    Hashimoto, K
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2006, 100 : 223P - 223P